-
HRP Rabbit Anti-Goat IgG (H+L) Antibody for p21
2026-09-24
Turn p21 mRNA–LNP experiments into interpretable protein-level evidence with a sensitive secondary antibody for goat primary antibodies. This workflow connects bladder-tumor biology to practical western blot, ELISA, and tissue-staining readouts while keeping assay-specific limits clear.
-
Berbamine hydrochloride in Cancer Research
2026-09-24
Use Berbamine hydrochloride to probe cancer-cell signaling and test how pathway perturbation relates to ferroptosis-associated phenotypes—without assuming it targets the METTL16–SENP3–LTF axis. This practical guide combines reported cell-line potency with a cautious, control-rich workflow for KU812 and HepG2 experiments.
-
p21–ELP Delivery Suppresses Glioblastoma Proliferation
2026-09-23
Quinn and colleagues tested an elastin-like polypeptide delivery platform for a p21-derived cell-cycle inhibitory peptide in three glioblastoma cell lines. The construct entered cells and reduced proliferation, with differences in sensitivity among models and generally limited apoptosis, supporting further study of its predominantly cytostatic effects.
-
FGFR3 Inhibition in SLC26A2 Chondrodysplasia
2026-09-23
The reference study combines genetic Fgfr3 ablation with pharmacological inhibition to show that excessive FGFR3 signaling contributes to SLC26A2-related chondrodysplasia in mice. NVP-BGJ398 improved chondrocyte behavior and skeletal phenotypes, supporting FGFR3 pathway modulation as a preclinical strategy while leaving important questions about human translation unresolved.
-
GLT-1, CB1-CREB Signaling, and TBI Cognition
2026-09-22
A 2025 Biomolecules study links traumatic brain injury to transient loss of astrocytic GLT-1 through a 2-AG–CB1–CREB signaling axis. In a mouse controlled cortical impact model, pharmacological CB1 blockade restored GLT-1, reduced neuronal apoptosis, and improved behavioral measures of cognitive dysfunction, identifying glutamate homeostasis as a mechanistically relevant target for memory impairment research.
-
Firefly Luciferase mRNA: Workflow & Optimization
2026-09-22
Build more reproducible gene expression, cell viability, and delivery assays with an ARCA-capped, 5-methoxyuridine-modified luciferase transcript. This practical guide covers handling, transfection controls, bioluminescent readouts, LNP comparisons, and troubleshooting for cell-based and in vivo workflows.
-
MK-1775: Wee1 Kinase Inhibitor Workflows
2026-09-21
Learn how to deploy MK-1775 in checkpoint, viability, and combination-treatment assays without confusing growth arrest with cell death. This workflow emphasizes p53-aware model selection, time-resolved readouts, and practical troubleshooting for DNA damage response studies.
-
Y-27632 Dihydrochloride in Organelle-Aware Assays
2026-09-21
Y-27632 dihydrochloride is a selective ROCK inhibitor with a new role in organelle-aware assay design. This article connects ROCK-dependent cytoskeletal control with intestinal stem cell regeneration while distinguishing established evidence from testable experimental hypotheses.
-
Calnexin Shapes CFTR Variant Rescue and Drug Response
2026-09-20
Tedman et al. systematically examined how the ER chaperone calnexin influences expression and pharmacological rescue across 232 clinical CFTR variants. Their deep mutational scanning study shows that calnexin dependence is strongly variant- and domain-specific, providing a mechanistic framework for interpreting heterogeneous responses to CFTR modulators and designing more individualized cystic fibrosis research strategies.
-
Meropenem for Carbapenem Resistance Research
2026-09-19
Meropenem is a β-lactam antibiotic carbapenem for linking antibacterial phenotypes with carbapenemase, plasmid-transfer, and infection-model data. This workflow-focused guide shows how to control compound handling, design comparative assays, and interpret resistance results without confusing research observations with clinical treatment decisions.
-
Dual-Recombinase Tracing Tests Mouse Neo-Oogenesis
2026-09-18
Xie, Zhou, and Zheng use complementary Cre-loxP and Dre-rox lineage-tracing systems to test whether postnatal ovarian cells generate new oocytes in mice. Across physiological aging and busulfan-induced ovarian injury, the study detected no labeled growing oocytes or metaphase II eggs from non-pre-existing ovarian cells, strengthening the evidence against in vivo postnatal neo-oogenesis.
-
Ivermectin Workflows for Parasitology Research
2026-09-18
Build reproducible parasite assays with Ivermectin by controlling solvent, concentration, exposure time, and storage. This workflow also shows how a recent Gasdermin C study can improve assay interpretation without overstating evidence for oncology applications.
-
Nirmatrelvir: From 3CLpro Mechanism to Translation
2026-09-17
Nirmatrelvir (PF-07321332) offers translational researchers a well-defined way to connect SARS-CoV-2 polyprotein processing with measurable replication inhibition. This thought-leadership guide interprets the 3CLpro mechanism, evaluates docking evidence, outlines assay strategy, and positions a quality-controlled research reagent within antiviral therapeutics research.
-
Dual HER2–VEGFR-2 Targeting in Breast Cancer
2026-09-17
A 2026 study examined Lapatinib and Telatinib as a dual tyrosine kinase strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Combined treatment reduced proliferation, invadopodia formation, and two-dimensional tube formation, supporting further phenotype-first investigation while leaving direct target engagement and combination synergy unresolved.
-
MOG (35-55) Peptide: EAE Workflow Guide
2026-09-16
Build reproducible experimental autoimmune encephalomyelitis studies with a defined myelin oligodendrocyte glycoprotein peptide, from dissolution and dosing to pathway-aware readouts. This guide connects practical MOG (35-55) workflows with emerging PARP7–STAT1/STAT2 biology for more informative multiple sclerosis research.